These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clofibrate myopathy: a case report and a review of the literature. Rush P; Baron M; Kapusta M Semin Arthritis Rheum; 1986 Feb; 15(3):226-9. PubMed ID: 3515563 [No Abstract] [Full Text] [Related]
8. Untoward effects of clofibrate in hemodialyzed patients. Kijima Y; Sasaoka T; Kanayama M; Kubota S N Engl J Med; 1977 Mar; 296(9):515. PubMed ID: 834232 [No Abstract] [Full Text] [Related]
9. Creatinekinase in hyperlipoproteinemic patients treated with clofibrate. Schneider J; Mühlfellner G; Kaffarnik H Artery; 1980; 8(2):164-70. PubMed ID: 7458683 [TBL] [Abstract][Full Text] [Related]
10. Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. Scott KR; Simmons Z; Boyer PJ Muscle Nerve; 2002 Jul; 26(1):141-4. PubMed ID: 12115960 [TBL] [Abstract][Full Text] [Related]
11. Clofibrate, serum enzymes, and muscle pain. Smith AF; Macfie WG; Oliver MF Br Med J; 1970 Apr; 2(5701):86-8. PubMed ID: 5420239 [TBL] [Abstract][Full Text] [Related]
12. Control of clofibrate toxicity in uremic hypertriglyceridemia. Goldberg AP; Sherrard DJ; Haas LB; Brunzell JD Clin Pharmacol Ther; 1977 Mar; 21(3):317-25. PubMed ID: 837651 [TBL] [Abstract][Full Text] [Related]
13. Clofibrate-induced acute muscular syndrome. Sekowski I; Samuel P Am J Cardiol; 1972 Oct; 30(5):572-4. PubMed ID: 5073673 [No Abstract] [Full Text] [Related]
14. Monitoring of the serum levels of muscle enzymes during replacement therapy in hypothyroidism with myopathy. Giampietro O; Boni C; Carpi A; Buzzigoli G J Nucl Med Allied Sci; 1981; 25(4):211-8. PubMed ID: 7343654 [No Abstract] [Full Text] [Related]
15. [Hypolipemic property and myotoxic action of clofibrate in a case of nephrotic syndrome]. Fabre J; Denizot M; Wildi E; Micheli H; Berthoud S Schweiz Rundsch Med Prax; 1973 Jun; 62(23):732-7. PubMed ID: 4705828 [No Abstract] [Full Text] [Related]
17. Clofibrate-induced complications in renal disease: a case report. Pokroy N; Ress S; Gregory MC S Afr Med J; 1977 Nov; 52(20):806-8. PubMed ID: 204061 [TBL] [Abstract][Full Text] [Related]
18. [Muscle toxicity of hypolipidemic agents revealed in hypothyroidism]. Prudhomme F; Jacotot B Presse Med; 2003 Apr; 32(13 Pt 1):603-4. PubMed ID: 12718321 [No Abstract] [Full Text] [Related]
19. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia]. Colombo L; Monarca A; Goldberg D; Zanetta R Clin Ter; 1979 Oct; 91(2):155-71. PubMed ID: 540479 [No Abstract] [Full Text] [Related]
20. Acute muscular syndrome associated with administration of clofibrate. Langer T; Levy RI N Engl J Med; 1968 Oct; 279(16):856-8. PubMed ID: 5677720 [No Abstract] [Full Text] [Related] [Next] [New Search]